| Literature DB >> 31718088 |
Vedud Purde1,2, Florian Busch1,3, Elena Kudryashova1, Vicki H Wysocki1,2,3,4, Dmitri S Kudryashov1,2.
Abstract
Actin-depolymerizing factor (Entities:
Keywords: actin depolymerization; actin severing; coiled coils; cyclase-associated proteins; oligomerization; α-barrels
Mesh:
Substances:
Year: 2019 PMID: 31718088 PMCID: PMC6888645 DOI: 10.3390/ijms20225647
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Domain structure of CAP proteins: (a) schematic representation of the full-length (FL) CAP domain structure and the truncation constructs used in this study. Amino acid numbering is shown for CAP1 only. CC: coiled coil domain (pink); HFD: helical folded domain (grey); P1 and P2: polyproline-rich regions (yellow); WH2: Wiskott-Aldrich syndrome protein (WASP)-homology 2 domain (cyan); CARP: C-terminal β-sheet domain (green); DD: dimerization domain; TD: trimerization domain. (b) Protein sequence alignment of human CAP1 and CAP2. Asterisks represent identical residues (64.1% identity) between the two isoforms. The underlined sequence with a predicted high helical propensity was used in CCBUILDER 2.0 for modeling coiled-coil oligomerization (see Figure 3). Domain abbreviation and coloring as in (a).
Figure 2Oligomerization state of the N-terminal constructs of human CAPs: (a) sedimentation velocity analytical ultracentrifugation (SV-AUC) data were analyzed using SEDFIT software with a continuous sedimentation coefficient distribution model c(S). (b) Raw m/z data obtained by native mass spectrometry (MS) were deconvoluted with UniDec 4.0 and the molecular weights of the constructs were calculated. Numbers in the graphs indicate the oligomeric state of the CAP constructs present in solution: 1—monomer, 2—dimer, 3—trimer, 4—tetramer.
Molecular weights (MW) of recombinant CAP constructs determined by SV-AUC and native MS. (ƒ) —frictional ratio; (S)—sedimentation coefficient.
| AUC (ƒ) | AUC (S) | AUC MW (kDa) | MS MW (kDa) | Theoretical MW (kDa) | |
|---|---|---|---|---|---|
| ΔCC-N-CAP1 | 1.97 | 1.36 | 25.30 | 23.25 | 23.48 (monomer) |
| DD-N-CAP1 | 2.02 | 2.53 | 60.40 | 66.03 | 66.10 (dimer) |
| TD-N-CAP1 | 1.97 | 3.33 | 92.3 | 97.60 | 97.46 (trimer) |
| N-CAP1 | 2.17 | 3.43 | 92.1 | 101.46 | 101.46 (tetramer) |
| ΔCC-N-CAP2 | 2.07 | 1.62 | 23.50 | 23.69 | 23.69 (monomer) |
| DD-N-CAP2 | 1.44 | 3.78 | 66.8 | 66.63 | 66.52 (dimer) |
| TD-N-CAP2 | 1.41 | 4.84 | 92.3 | 98.36 | 98.03 (trimer) |
| N-CAP2 | 2.17 | 3.54 | 102.00 | 102.34 | 102.34 (tetramer) |
Figure 3Modeling oligomerization of the N-terminal constructs of human CAPs: the CCBUILDER 2.0 web application (http://coiledcoils.chm.bris.ac.uk/ccbuilder2) was used to model the oligomeric coiled-coil structures of CAP1 (shown) and CAP2 N-terminal helices. The most stable tetramers (a–e) and hexamers (f–j) with the lowest energies are shown from three perspectives: side view (a,f), and along the helices from the N- (d,i), and C-termini (e,j). Schematic helical wheel diagrams show the relative orientations of the helices in the oligomers (b,g) and an enlarged view of the highlighted helices (c,h). Green shaded areas represent the hydrophobic cores of the oligomers. Up to four salt bridges between Arg and Asp/Glu residues contribute to the stabilization of each pair of neighboring helices (shown as yellow dotted lines in (f)). (k) Hypothetical stabilization of the hexamer structure by a fatty acid (blue) occupying the central, hydrophobic channel of Srv2/CAP (see Section 3). A low-energy CAP2 structure generated in CCBUILDER is shown. (l) The N-terminal coiled coil sequence of CAP1 (top row), with the conventional “a–f” designation of the heptad amino acids (middle row) and the hydrophobicity pattern (bottom row) characteristic of trimeric/tetrameric (xxhxxhh) and higher-order (xhhxxhh) coiled-coil structures. Residues involved in stabilization of the hydrophobic cores are designated by “h” in the hydrophobicity pattern and by green color elsewhere. Notice that in the hexamer, Cβ-Cγ atoms of the underlined Arg residues (l) contribute to the stabilization of the hydrophobic core (red arrows in (j).
Predicted energies of N-terminal coiled-coil (CC) oligomers of human CAPs: provided values are means and standard deviations of 10 best scores of twenty Bristol University Docking Engine (BUDE) energies calculated by CCBUILDER 2.0.
| Oligomeric State | BUDE Energy | |
|---|---|---|
| N-terminal CC of CAP1 | Tetramer | −398.7 ± 13.7 |
| Pentamer | −671.4 ± 10.2 | |
| Hexamer | −857.1 ± 73.0 | |
| Heptamer | −916.4 ± 42.5 | |
| N-terminal CC of CAP2 | Tetramer | −388.5 ± 15.4 |
| Pentamer | −601.2 ± 15.4 | |
| Hexamer | −831.6 ± 65.1 | |
| Heptamer | −878.6 ± 23.2 |
Figure 4Comparison of F-actin binding affinities of human N-CAP constructs. CAP binding affinities to F-actin were analyzed by high-speed (300,000× g) cosedimentation: (a) representative sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of supernatant (S) and pellet (P) fractions of N-CAP1 co-pelleted with F-actin (uncropped version of the gel is shown in Supplementary Figure S2); (b–f) binding curves with error bars representing the standard errors of the mean of three independent repetitions; (g) Kd values determined by fitting the experimental data to the binding isotherm equation defined in the Section 4.4.
Figure 5Effects of N-CAP oligomers on cofilin-mediated F-actin disassembly in bulk pyrene–actin depolymerization assays. Depolymerization of preassembled pyrene-labeled (10%) F-actin from the pointed ends (in the presence of CapZ) was initiated by the addition of a G-actin-sequestering drug latrunculin B along with 250 nM CFL1 (a,b) or CFL2 (c,d) in the absence of presence of 750 nM N-CAP1 (a,c) or N-CAP2 (b,d) oligomeric constructs. For clarity, error bars representing standard errors of the mean from three (CFL1) and four (CFL2) independent experiments are shown for every third data point.
Effects of N-CAP constructs on cofilin-mediated F-actin depolymerization rates. Initial rates of F-actin depolymerization were measured from the slopes of the pyrene–actin depolymerization curves during the first 500 seconds. Rates are expressed in nM/min as mean values with standard errors from three (CFL1) and four (CFL2) experiments.
| No CAPs | CAP1 | CAP2 | |
|---|---|---|---|
| Actin alone | 12.9 ± 2.8 | ||
| CFL1 | 44.0 ± 4.0 | ||
| CFL1 + ΔCC-N-CAP | 44 ± 4.0 | 48 ± 6.9 | |
| CFL1 + DD-N-CAP | 52 ± 4.0 | 52 ± 4.0 | |
| CFL1 + TD-N-CAP | 60 ± 12 | 64 ± 4.0 | |
| CFL1 + N-CAP | 72 ± 3.4 | 68 ± 14 | |
| CFL2 | 15.8 ± 6.5 | ||
| CFL2 + ΔCC-N-CAP | 24 ± 4.0 | 12 ± 1.4 | |
| CFL2 + DD-N-CAP | 30 ± 0.8 | 48 ± 3.5 | |
| CFL2 + TD-N-CAP | 42 ± 6.0 | 44 ± 4.0 | |
| CFL2 + N-CAP | 39 ± 4.0 | 48 ± 2.1 |
Figure 6Effects of N-CAP constructs on cofilin-mediated F-actin severing observed by total internal reflection fluorescence (TIRF) microscopy. (a) Representative time-lapse images of Alexa 488-labeled F-actin severing upon addition of CFL1 in the absence or presence of N-CAP1 constructs. Arrows indicate severing events. (b–d) Analysis of severing activities: each data point represents the mean value of the number of severing events per micron of filament from three independent experiments (10–15 filaments per experiment). For clarity, error bars representing standard deviations of the mean are shown for every third data point.
Figure 7Interaction of native CAP1 with cofilin isoforms in cells: (a) western blot analysis demonstrates the specificity of the primary isoform-specific anti-CFL1, anti-CFL2, and anti-CAP1 antibodies used in immunofluorescence proximity ligation assay (PLA) experiments. WCL: whole-cell lysate. Uncropped versions of the blots are shown in Supplementary Figures S4 and S5. (b) Duolink in situ PLA assay performed on Hs 578T cells, as described in the Section 4.8. Cells stained using a single primary antibody (CFL1 only, CFL2 only, and CAP1 only) are shown as negative controls. PLA signal (magenta) using pairs of CFL1/CAP1 and CFL2/CAP1 antibodies represents CAP1/cofilin interaction events. Cells were counter-stained with fluorescein isothiocyanate (FITC)–phalloidin for F-actin (green) and nuclear 4′,6-diamidino-2-phenylindole (DAPI, blue). Scale bar is 20 μm.